Revlimid squeaks through revised NICE appraisal
This article was originally published in Scrip
Executive Summary
Concessions by Celgene during an assessment of Revlimid (lenalidomide) for the treatment of multiple myeloma have persuaded the National Institute for health and Clinical Excellence (NICE) to consider recommending it for use in the national health service in England and Wales in certain circumstances.